Actuate Therapeutics (NASDAQ:ACTU) Trading Down 2.1% – Should You Sell?

Actuate Therapeutics (NASDAQ:ACTU)’s share price fell 2.1% on Tuesday . The stock traded as low as $7.85 and last traded at $8.11. 42,680 shares traded hands during trading, an increase of 5% from the average session volume of 40,795 shares. The stock had previously closed at $8.28.

Actuate Therapeutics Stock Performance

The firm’s 50 day moving average is $8.36.

Institutional Trading of Actuate Therapeutics

A hedge fund recently bought a new stake in Actuate Therapeutics stock. Northwestern University acquired a new position in shares of Actuate Therapeutics (NASDAQ:ACTU) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 27,778 shares of the company’s stock, valued at approximately $207,000. Actuate Therapeutics makes up 0.2% of Northwestern University’s holdings, making the stock its 5th biggest holding. Northwestern University owned approximately 0.14% of Actuate Therapeutics as of its most recent SEC filing.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.